Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

Chapter: 4 DICLOFENAC MARKET, BY INDICATION

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. OSTEOARTHRITIS

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. ANKYLOSING SPONDYLITIS

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. DYSMENORRHEA

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. RHEUMATOID ARTHRITIS

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast

4.6. MIGRAINE

4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast

4.7. PAIN

4.7.1. Key market trends
4.7.2. Growth factors and opportunities
4.7.3. Market size and forecast

4.8. OTHERS

4.8.1. Key market trends
4.8.2. Growth factors and opportunities
4.8.3. Market size and forecast

Chapter: 5 DICLOFENAC MARKET, BY FORMULATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ORAL

5.2.1. Market size and forecast

5.3. PARENTERAL

5.3.1. Market size and forecast

Chapter: 6 DICLOFENAC MARKET, BY REGION

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.2.4. North America Diclofenac Market by Indication
6.2.5. North America Diclofenac Market by Formulation

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast

6.3.4. Europe Diclofenac Market by Indication
6.3.5. Europe Diclofenac Market by Formulation

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. South Korea market size and forecast
6.4.3.6. Rest of Asia-Pacific market size and forecast

6.4.4. Asia-Pacific Diclofenac Market by Indication
6.4.5. Asia-Pacific Diclofenac Market by Formulation

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Brazil market size and forecast
6.5.3.2. Saudi Arabia market size and forecast
6.5.3.3. South Africa market size and forecast
6.5.3.4. Rest of LAMEA market size and forecast

6.5.4. LAMEA Diclofenac Market by Indication
6.5.5. LAMEA Diclofenac Market by Formulation

Chapter: 7 COMPANY PROFILES

7.1. AURO LABORATORIES LIMITED

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.2. HENAN DONGTAI PHARMACEUTICAL CO.

7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments

7.3. BAYER AG

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.4. PFIZER INC.

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. HUNAN WARRANT PHARMACEUTICAL CO., LTD.

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. NOVARTIS AG 

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments

7.7. XIANSHI PHARMACEUTICAL GROUP 

7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments

7.8. MERCK & CO., INC.

7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments

7.9. ISTITUTO BIOCHIMICO ITALIANO G. LORENZINI S.P.A.

7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments

7.10. DEZHOU DEYAO PHARMACEUTICAL CO., LTD.

7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments